These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 17274759)

  • 1. Quantitative measurement of anti-TSH receptor antibodies is useful for the evaluation of treatment effect.
    Amino N; Kubota S; Morita S; Fukata S; Miyauchi A
    Thyroid; 2007 Jan; 17(1):85-6. PubMed ID: 17274759
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
    Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A TSHR-LH/CGR chimera that measures functional thyroid-stimulating autoantibodies (TSAb) can predict remission or recurrence in Graves' patients undergoing antithyroid drug (ATD) treatment.
    Giuliani C; Cerrone D; Harii N; Thornton M; Kohn LD; Dagia NM; Bucci I; Carpentieri M; Di Nenno B; Di Blasio A; Vitti P; Monaco F; Napolitano G
    J Clin Endocrinol Metab; 2012 Jul; 97(7):E1080-7. PubMed ID: 22492869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical value of M22-based assays for TSH-receptor antibody (TRAb) in the follow-up of antithyroid drug treated Graves' disease: comparison with the second generation human TRAb assay.
    Massart C; Gibassier J; d'Herbomez M
    Clin Chim Acta; 2009 Sep; 407(1-2):62-6. PubMed ID: 19576193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence of thyrotropin (TSH) receptor antibodies in children and adolescents with Graves' disease treated using antithyroid medication.
    Smith J; Brown RS
    Thyroid; 2007 Nov; 17(11):1103-7. PubMed ID: 17822376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concentration of TSH-receptor antibodies (TBII) in the sera of patients with immunogenic hyperthyroidism (Graves' disease) receiving antithyroid medication.
    Budihna N; Pavlin K; Porenta M
    Radiobiol Radiother (Berl); 1987; 28(1):101-6. PubMed ID: 2438715
    [No Abstract]   [Full Text] [Related]  

  • 7. [Clinical usefulness of the assay of TSH-binding inhibitor immunoglobulins (TBII) in patients with Graves' disease: Effect of antithyroid drug treatment on TBII and prognosis].
    Iida Y; Konishi J; Kousaka T; Misaki T; Nakajima T; Endo K; Torizuka K
    Kaku Igaku; 1983 Dec; 20(10):1425-31. PubMed ID: 6202910
    [No Abstract]   [Full Text] [Related]  

  • 8. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
    Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE
    Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
    Takasu N; Yamashiro K; Komiya I; Ochi Y; Sato Y; Nagata A
    Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in TSH receptor antibody levels (TRAb) as markers of effectiveness of various therapies in Graves-Basedow's disease.
    Bojarska-Szmygin A; Janicki K; Pietura R; Janicka L
    Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):248-53. PubMed ID: 15314994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The effect of thyrostatic treatment on circulating thyrotropin-receptor antibodies in Basedow's disease].
    Lozanov B; Kirilov G; Ivanova R; Khubaveshki S
    Vutr Boles; 1990; 29(3):79-84. PubMed ID: 1704667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thyrotropin receptor autoantibodies are associated with continued thyrotropin suppression in treated euthyroid Graves' disease patients.
    Brokken LJ; Wiersinga WM; Prummel MF
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4135-8. PubMed ID: 12970276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences between changes in serum thyrotropin-binding inhibitory antibodies and thyroid-stimulating antibodies in the course of antithyroid drug therapy for Graves' disease.
    Yamano Y; Takamatsu J; Sakane S; Hirai K; Kuma K; Ohsawa N
    Thyroid; 1999 Aug; 9(8):769-73. PubMed ID: 10482368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
    Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
    Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The challenge of treating Graves'-Basedow's disease patients with antithyroid drugs (ATD) in a large university hospital.
    Iacona A; Lima N; Perozim LM; Knobel M; Cavaliere H; Medeiros-Neto G
    Exp Clin Endocrinol; 1991 May; 97(2-3):297-302. PubMed ID: 1717299
    [No Abstract]   [Full Text] [Related]  

  • 16. Epitope mapping of tsh receptor-blocking antibodies in Graves' disease that appear during pregnancy.
    Kung AW; Lau KS; Kohn LD
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3647-53. PubMed ID: 11502791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anti-TSH receptor antibody (TBII, TSAb)].
    Amino N; Kubota S
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():277-9. PubMed ID: 16149508
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical applications of assays for thyrotropin-receptor antibodies in Graves' disease.
    Ginsberg J; von Westarp C
    CMAJ; 1986 May; 134(10):1141-7. PubMed ID: 2421862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of remission or relapse for Graves' hyperthyroidism by the combined determination of stimulating, blocking and binding TSH-receptor antibodies after the withdrawal of antithyroid drug treatment.
    Wallaschofski H; Miehle K; Mayer A; Tuschy U; Hentschel B; Paschke R
    Horm Metab Res; 2002 Jul; 34(7):383-8. PubMed ID: 12189586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithyroid drugs inhibit radioiodine-induced increases in thyroid autoantibodies in hyperthyroid Graves' disease.
    Nakazato N; Yoshida K; Mori K; Kiso Y; Sayama N; Tani JI; Nakagawa Y; Ito S
    Thyroid; 1999 Aug; 9(8):775-9. PubMed ID: 10482369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.